Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Rhinomed Limited
  6. News
  7. Summary
    RNO   AU000000RNO1

RHINOMED LIMITED

(RNO)
End-of-day quote. End-of-day quote Australian Stock Exchange - 11/26
0.27 AUD   +5.88%
11/18RHINOMED : CEO presentation to 2021 AGM
PU
11/10Investor update November 2021
PU
10/26Rhinomed Secures Ethics Approval for Post-Market Trial of Nasal Swab Product
MT
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Rhinomed Limited Appoints Rhinoswab Distributors for Australia and Belgium, the Netherlands and Luxembourg

09/13/2021 | 09:05pm EST

Rhinomed Limited announced appointment of AntiMicrobial Technologies Group (AMT Group Australia Pty Ltd) as a distributor of Rhinoswab in Australia and BioTrading Benelux BV as a distributor in Belgium, the Netherlands and Luxembourg (Benelux). Rhinomed announced that it has appointed AMT Group Australia Pty Ltd. and BioTrading Benelux BV as distributors of the Rhinoswab and Rhinoswab Junior. The distribution agreement with AMT Group Australia Pty Ltd. is for an initial term of 12 months and provides AMTG the non-exclusive right to sell the Rhinoswab in Australia. The agreement is effective as of 19 August 2021. The distribution agreement with BioTrading Benelux BV is for an initial three year term. BioTrading Benelux BV has been granted an exclusive right to sell the Rhinoswab in Belgium, the Netherlands and Luxembourg. BioTrading Benelux BV serves the biotechnology, pharmaceutical and clinical industries (https://biotrading.com). The agreement is effective as of 31 August 2021. The agreements provide the distributor the right to sell the Rhinoswab in the territories, but does not inhibit Rhinomed's ability to sell or supply the Rhinoswab to Rapid antigen testing companies competing in those markets. Other terms of the distribution agreements are standard for agreements of this nature.


ę S&P Capital IQ 2021
All news about RHINOMED LIMITED
11/18RHINOMED : CEO presentation to 2021 AGM
PU
11/10Investor update November 2021
PU
10/26Rhinomed Secures Ethics Approval for Post-Market Trial of Nasal Swab Product
MT
10/26Rhinoswab Clinical Trial Approves At St Vincent's Hospital
CI
10/19RHINOMED : New swab takes away children's fear of swabbing
EQ
09/28Rhinomed Limited Auditor Raises 'Going Concern' Doubt
CI
09/13Rhinomed Limited Appoints Rhinoswab Distributors for Australia and Belgium, the Netherl..
CI
09/10RHINOMED : to Deliver One Million COVID-19 Nasal Swabs to Australia's Victoria Government
MT
09/09Rhinomed Limited Receives an Initial Purchase Order for One Million Rhinoswabs from the..
CI
08/26Rhinomed Limited Announces Ethics Approval Granted for Clinical Trial of First Nasal Sw..
CI
More news
Financials
Sales 2021 4,42 M 3,15 M 3,15 M
Net income 2021 -8,64 M -6,15 M -6,15 M
Net cash 2021 1,87 M 1,33 M 1,33 M
P/E ratio 2021 -4,55x
Yield 2021 -
Capitalization 68,5 M 48,8 M 48,8 M
EV / Sales 2020 2,37x
EV / Sales 2021 8,48x
Nbr of Employees -
Free-Float 10,1%
Chart RHINOMED LIMITED
Duration : Period :
Rhinomed Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RHINOMED LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Managers and Directors
Michael Johnson Chief Executive Officer, MD & Executive Director
Sean Slattery Chief Financial Officer & Secretary
Ronald R. Dewhurst Non-Executive Chairman
Brent J. Scrimshaw Independent Non-Executive Director
Eric Knight Independent Non-Executive Director
Sector and Competitors